Amarin Corp PLC (AMRN)
0.8545
-0.03
(-2.90%)
USD |
NASDAQ |
May 10, 16:00
0.8545
0.00 (0.00%)
After-Hours: 20:00
Amarin Enterprise Value: 53.39M for May 9, 2024
Enterprise Value Chart
Historical Enterprise Value Data
| Date | Value |
|---|---|
| May 09, 2024 | 53.39M |
| May 08, 2024 | 46.36M |
| May 07, 2024 | 92.46M |
| May 06, 2024 | 94.47M |
| May 03, 2024 | 65.71M |
| May 02, 2024 | 69.00M |
| May 01, 2024 | 36.66M |
| April 30, 2024 | 70.19M |
| April 29, 2024 | 52.15M |
| April 26, 2024 | 51.29M |
| April 25, 2024 | 45.09M |
| April 24, 2024 | 52.69M |
| April 23, 2024 | 54.62M |
| April 22, 2024 | 47.40M |
| April 19, 2024 | 44.77M |
| April 18, 2024 | 49.90M |
| April 17, 2024 | 68.51M |
| April 16, 2024 | 59.80M |
| April 15, 2024 | 69.12M |
| April 12, 2024 | 84.90M |
| April 11, 2024 | 110.77M |
| April 10, 2024 | 118.99M |
| April 09, 2024 | 127.20M |
| April 08, 2024 | 131.31M |
| April 05, 2024 | 123.09M |
| Date | Value |
|---|---|
| April 04, 2024 | 127.20M |
| April 03, 2024 | 127.20M |
| April 02, 2024 | 98.45M |
| April 01, 2024 | 54.09M |
| March 31, 2024 | 57.70M |
| March 28, 2024 | 36.87M |
| March 27, 2024 | 36.23M |
| March 26, 2024 | 26.91M |
| March 25, 2024 | 18.04M |
| March 22, 2024 | 24.39M |
| March 21, 2024 | 25.11M |
| March 20, 2024 | 39.36M |
| March 19, 2024 | 27.52M |
| March 18, 2024 | 15.27M |
| March 15, 2024 | 24.06M |
| March 14, 2024 | 9.214M |
| March 13, 2024 | 25.71M |
| March 12, 2024 | 26.31M |
| March 11, 2024 | 38.87M |
| March 08, 2024 | 49.83M |
| March 07, 2024 | 51.40M |
| March 06, 2024 | 60.31M |
| March 05, 2024 | 57.06M |
| March 04, 2024 | 50.19M |
| March 01, 2024 | 104.78M |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
-51.19M
Minimum
Nov 02 2023
8.066B
Maximum
Dec 13 2019
1.749B
Average
1.051B
Median
Nov 10 2020
Enterprise Value Benchmarks
| Trinity Biotech PLC | 66.79M |
| DBV Technologies SA | -30.45M |
| Cellectis SA | 64.36M |
| Adaptimmune Therapeutics PLC | 131.97M |
| Akari Therapeutics PLC | 9.110M |
Enterprise Value Related Metrics
| Net Income (Quarterly) | -9.953M |
| Revenue (Quarterly) | 56.52M |
| Total Expenses (Quarterly) | 70.10M |
| EPS Diluted (Quarterly) | -0.02 |
| Gross Profit Margin (Quarterly) | 56.45% |
| Profit Margin (Quarterly) | -17.61% |
| Earnings Yield | -15.21% |
| Normalized Earnings Yield | -12.18 |